摘要
近年来,过敏性哮喘在全球范围内的患病率仍持续上升,严重影响着哮喘患者的身心健康。IgE的增长是过敏性哮喘症状持续和恶化的重要因素,促进IgE活性的降低,可以从根源上阻断过敏性哮喘发作的炎症级联反应。奥马珠单抗作为第一个抗IgE人源化单克隆抗体,其通过抑制IgE引导的变态反应,在中重度过敏性哮喘治疗中的有效性及安全性已得到证实,开创了哮喘生物靶向药物治疗的新领域。本文旨在论述近年来国内外奥马珠单抗在中重度过敏性哮喘治疗中的临床应用进展,评价其有效性及安全性,并对多项临床检验指标与奥马珠单抗治疗疗效之间的关系做一综述。
In recent years, the prevalence of allergic asthma continues to rise worldwide, which seriously af-fects the physical and mental health of asthmatic patients. The increase of IgE is an important factor in the persistence and deterioration of allergic asthma symptoms, and promoting the decrease of IgE activity can block the inflammatory cascade of allergic asthma attack from the root. Omazumab, as the first anti-IGE humanized monoclonal antibody, has been proven to be effective and safe in the treatment of moderate-to-severe allergic asthma by inhibiting IgE induced allergic reactions, cre-ating a new field of biological targeted drug therapy for asthma. This article aims to review the clin-ical application of omalizumab in the treatment of moderate to severe allergicasthma in recent years, evaluate its efficacy and safety, and review the relationship between a number of clinical in-dicators and the therapeutic effect of omalizumab.
出处
《临床医学进展》
2023年第7期11043-11049,共7页
Advances in Clinical Medicine
